Sustained Delivery of Interleukin-2 from a Poloxamer 407 Gel Matrix Following Intraperitoneal Injection in Mice

Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists

Volumn 9, Issue 3, 1992, Pages 425-434

  Johnston, Thomas P ^a   Punjabi, Monika A ^b   Froelich, Christopher J ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BD Technologies   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

biological response modifiers; cancer immunotherapy; Pluronic F 127; poloxamer 407; recombinant interleukin 2

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; DRUG VEHICLE; POLOXAMER; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CYTOTOXICITY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; SUSTAINED RELEASE PREPARATION;

ANIMAL; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HUMAN; IN VITRO; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-2; MALE; MICE; MICE, INBRED STRAINS; POLOXALENE; SUPPORT, NON-U.S. GOV'T;

EID: 0026542159     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1023/A:1015815624334     Document Type: Article

References (26)

1. T-cell growth factor
2. In vivo interleukin-2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells
3. Regression of established pulmonary metastasis and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2
4. Inhibition of cytotoxic T-cell clonal expansion by cyclophosphamide and the recovery of cytotoxic T-lymphocyte precursors by supernatants from mixed-lymphocyte cultures
5. T-cell factor (interleukin-2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice
6. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2
7. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastasis by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2
8. Lymphokine-activated killer phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes
9. Interleukin-2 (IL-2) administration in vivo: Influence of IL-2 route and timing on T cell growth
10. The fate of interleukin-2 after in vivo administration
11. Systemic administration of recombinant interleukin-2 stimulates in vivo lymphoid cell proliferation in tissues
12. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2
13. Inulin disposition following intramuscular administration of an inulin/poloxamer gel matrix
14. Sustained release of urease from a poloxamer gel matrix
15. Toxicological evaluation of poloxamers for intramuscular use
16. The kinetics of the sol-to-gel transition for poloxamer polyols
17. Isolation and fractionation of lymphocytes
18. Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin-2
19. Application of an interleukin-2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases
20. R gel
21. Main characteristics of proteins in native and denatured states
22. Parenteral formulation of proteins and peptides: Stability and stabilizers
23. The adjuvant activity of nonionic block polymer surfactants: The role of hydrophile-lipophile balance